Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666601 · ClinicalTrials.gov registry record · Phase 1
Microdialysis and Pharmacokinetic Study of TR-701
A Phase 1 study, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00666601 is a Phase 1 study that has completed, run by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 15 participants.
The verdict
NCT00666601, a Phase 1 study, has completed, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the penetration of TR-700 into subcutaneous adipose tissue and skeletal muscle after a single oral dose of 600 mg TR-701
Interventions
- DRUG TR-700 (active moiety)
- DRUG TR-701 (pro-drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-04-04 |
| Est. Completion | 2008-08-12 |
| Phase | Phase 1 |
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)18 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00666601
The ClinicalTrials.gov registry entry for NCT00666601 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TR-700 (active moiety) is the first listed.
NCT00666601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00666601 about?
NCT00666601 is a clinical study titled "Microdialysis and Pharmacokinetic Study of TR-701". The purpose of this study is to measure the penetration of TR-700 into subcutaneous adipose tissue and skeletal muscle after a single oral dose of 600 mg TR-701
What is the current status of trial NCT00666601?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-04-04. Estimated completion is 2008-08-12.
What interventions are being tested in trial NCT00666601?
The interventions under investigation include: TR-700 (active moiety) (DRUG), TR-701 (pro-drug) (DRUG).
Who is sponsoring clinical trial NCT00666601?
This trial is sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.